Alamag

Quick links to important sections

Alamag

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alamag

What is Alamag? (Overview)

Property Description
Active Ingredients Aluminum Hydroxide, Magnesium Hydroxide
Form Oral Suspension, Chewable Tablets
Pharmacological Class Antacid (Combination Aluminum/Magnesium)
Common Use Relief of symptoms from Gastric Hyperacidity
Origin Synthetic Inorganic Salts

What is Alamag and What Type of Medicine is It?

Alamag is a combination medicine classified as an antacid, primarily used for the immediate, temporary relief of symptoms caused by excess stomach acid. This non-prescription, Over-The-Counter (OTC) pharmaceutical preparation belongs to the antacid pharmacological group. Its general purpose is to effectively mitigate the burning and discomfort associated with gastric hyperacidity, including common instances of heartburn and acid indigestion. The formulation is clinically recognized for its quick onset of action, making it a reliable choice for acute, symptomatic episodes, such as acid reflux discomfort following a meal.

Composition: Aluminum Hydroxide and Magnesium Hydroxide

The therapeutic action of Alamag is derived from its two primary active ingredients [INN], Aluminum Hydroxide and Magnesium Hydroxide, which are synthetic inorganic salt compounds. The two components are combined to ensure a balanced physiological response. Aluminum Hydroxide is recognized for its potent ability to neutralize stomach acid but can cause constipation, while Magnesium Hydroxide also neutralizes acid but may accelerate intestinal motility. The formulation as a combination product strategically offsets these opposing effects, aiming for a consistent and predictable acid-neutralizing benefit.

Available Forms of Alamag

Alamag is widely available in two primary dosage forms: an Oral Suspension (a liquid formulation) and Chewable Tablets, both designed for oral administration. The Oral Suspension delivers the active synthetic inorganic salts mixed within an aqueous suspension vehicle, offering the potential for rapid dispersion. The solid Chewable Tablets contain the same active compounds stabilized by inert excipients.

Regulatory References

  1. MedlinePlus
  2. NIH StatPearls

What side effects are possible with Alamag?

Possible Side Effects and Safety Information

The safety profile of this aluminum and magnesium combination antacid is officially documented by government regulatory agencies. Adverse reactions are classified according to frequency and impact on body systems.

Gastrointestinal and Frequency Classifications

Adverse effects impacting the Gastrointestinal system are the most common official findings. The two main effects, diarrhea and constipation, are typically classified as uncommon in regulatory summaries of product characteristics (SmPC), reflecting the intended balancing action of the dual ingredients. Other gastrointestinal effects, such as abdominal pain, are also listed but with a frequency documented as not known.

Metabolic and Systemic Safety

Systemic effects are categorized under Metabolism and nutrition disorders. The label notes the potential for Hypermagnesemia (excess magnesium), Hyperaluminemia (excess aluminum), and Hypophosphatemia (low phosphate levels). The potential for Hypersensitivity reactions (e.g., pruritus, angioedema) is also documented, though their frequency is not known.

Population-Specific and Serious Safety Patterns

The most critical safety consideration is for patients with renal impairment (kidney disease). Regulatory labeling emphasizes that these individuals are at higher risk for aluminum and magnesium accumulation. Long-term exposure in renal patients is associated with documented serious adverse reactions including encephalopathy (brain disorder), dementia, and microcytic anemia.

Additionally, the profile notes that prolonged administration is linked to risks of Hypophosphatemia, which may lead to osteomalacia (bone softening). Certain conditions, such as severe abdominal pain or bowel obstruction, are noted as safety limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an acute overdosage of this combination antacid is defined by two domains: immediate gastrointestinal manifestations and the risk of severe systemic toxicity. Acute over-ingestion is documented to result in symptoms such as diarrhoea, vomiting, abdominal pain, and a bloated feeling with cramping pain.

Systemic Risks and High-Risk Populations

While severe symptomatic outcomes are generally described as unlikely in individuals with normal renal function, the ingestion of large, acute doses or chronic excessive exposure carries the risk of systemic toxicity. Severe outcomes may include the development of Hypermagnesemia and Hyperaluminemia.

Regulatory documents explicitly state that patients with renal function deficiency are at significantly increased risk of these severe systemic imbalances due to impaired clearance. Furthermore, high-dose intake has been associated with the potential for intestinal obstruction or ileus, with the elderly noted as a population at higher risk.

Mandated Emergency Action

Official labeling strictly mandates that individuals seek immediate medical attention and Contact a Poison Control Center right away for any suspected accidental overdose. Management is described as symptomatic and supportive treatment. Specific procedures documented for severe systemic accumulation include rehydration, forced diuresis, and the necessity of Haemodialysis in cases linked to renal impairment.

Therapeutic Uses of Alamag

What Alamag Treats: Main Uses and Benefits

Alamag provides essential symptomatic relief across key domains of acid-related gastrointestinal discomfort, focusing on the management of acute and distressing manifestations. This antacid is commonly used for relief of symptoms caused by excess stomach acid.

The medication helps address symptom clusters that may become intense or disruptive, such as the characteristic burning sensation in the chest known as heartburn, along with acid indigestion and sour stomach. In a clinical context, it is applied when supportive symptom management is appropriate for discomfort associated with conditions like Gastritis, Peptic Ulcer disease, Esophagitis, and episodic GERD.

The antacid combination is designed to provide supportive relief from acid-related pain and burning. This application offers supportive therapeutic benefit during phases where the patient experiences heightened discomfort or acute acid-related flares. It may assist with maintaining functional stability by easing the overall symptom load when discomfort interferes with daily routine.


Quick Fact: Relief for Acute Acid Symptoms

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Alamag, a combination antacid of Aluminum Hydroxide and Magnesium Hydroxide, is defined by strict population and health condition constraints detailed in official regulatory documentation.

Contraindications and Restrictions

Classification Population or Condition
Absolute Contraindication Patients with severe kidney failure or disease due to the risk of accumulation of aluminum and magnesium (hypermagnesemia) (Source 1.1, 2.4).
Patients with known allergy or hypersensitivity to the active ingredients (Source 1.2).
Restricted/Conditional Use Pediatric Patients: Use is not recommended in children younger than 12 years without specific medical advice (Source 1.2).
Chronic Use: The maximum Over-The-Counter (OTC) dosage must not be used for longer than two consecutive weeks, except under the advice of a physician (Source 1.2, 2.4).

Required Consultation

Official labels advise that a doctor should be consulted prior to use by patients who have existing kidney disease, are on a low-magnesium or low-sodium diet, or have other existing stomach/bowel conditions (Source 1.2, 2.4). For pregnancy and breastfeeding, while some authorities list no contra-indication, use should be discussed with a healthcare provider (Source 2.1).

What should I know about interactions with other medicines?

Alamag’s interaction profile is officially documented in prescribing information as primarily pharmacokinetic, arising from the antacid’s ability to bind with and alter the gastrointestinal absorption of other medicines. This interaction results in reduced systemic exposure, lowering the plasma concentration of various co-administered oral drugs. The interaction classifications defined by government authorities establish clear restrictions.

Formal Regulatory Restrictions

Co-administration with Sodium Polystyrene Sulfonate (SPS) is a formally documented contraindication. This restriction is explicitly stated in regulatory labels due to the specific risk of intestinal complications associated with the aluminum component.

Timing and Exposure Constraints

The pharmacokinetic interaction necessitates mandatory administration separation for several drug classes. Regulatory documents state that drugs highly susceptible to binding—including Tetracyclines, Fluoroquinolones (e.g., Ciprofloxacin), and Levothyroxine—must be administered at least two to six hours apart from Alamag. Other medicines prone to reduced absorption include Bisphosphonates and oral Iron salts/supplements.

Population-Specific Risk

A critical population-specific interaction is noted for patients with impaired renal function. Due to reduced renal clearance of the Magnesium Hydroxide component, these patients face an increased regulatory risk of developing hypermagnesemia.

Mechanism of Action

The mechanism of action for Alamag, a combination of aluminum hydroxide and magnesium hydroxide, centers on chemical acid-base neutralization within the gastric lumen, which is its primary biological target. Upon introduction, the hydroxide ions (OH^-) from the active ingredients rapidly interact with the free hydrogen ions (H^+) of hydrochloric acid (HCl). This interaction type follows a simple chemical reaction, consuming the acid and forming water and the corresponding chloride salts (AlCl3 and MgCl2).

This consumption of H^+ ions leads to a swift pathway modulation, specifically an elevation of the stomach's pH. The resulting higher pH environment causes the inactivation of the proteolytic enzyme pepsin, which requires a highly acidic pH for optimal activity. This is the main mechanistic cascade. The system-level physiological consequence includes the altered intestinal motility profile due to the formation of the chloride salts: magnesium chloride exerts an osmotic influence, while aluminum chloride has a local influence that can counterbalance the former.

Dosage and Administration Information

How to Use Alamag

Alamag, a combination antacid, is officially administered by the oral route and is available in two primary forms: an oral suspension and chewable tablets. Regulatory documentation provides clear constraints on dosage, frequency, and duration of use, standardizing its application for symptomatic purposes.


Official Administration Guidelines

Instruction Detail
Route of administration: Oral administration.
Dosing schedule (Adults): 10 mL to 20 mL of the oral suspension or 1 to 4 chewable tablets per dose.
Frequency: Dosing is administered up to 4 times a day.
Timing in relation to meals: Taken after meals and at bedtime.
Preparation requirements: The oral suspension container must be shaken well prior to measuring a dose. Chewable tablets must be chewed thoroughly.
Maximum Daily Dose (Adults): Not to exceed 80 mL of suspension or 16 tablets in a 24-hour period.
Duration Constraint: Continuous use is restricted to no more than two consecutive weeks without medical advice.

Population-Specific Usage Contexts

Official labeling defines specific contexts where professional guidance is required for proper administration. For use in children under 12 years of age, a physician's consultation is necessary prior to dose administration. Similarly, use in individuals with pre-existing kidney disease also requires the advice of a physician, establishing a procedural constraint for this specific population.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early Research in Disease X

Research has explored the effects of a combination of Agent A and Agent B in individuals with Disease X. These early-phase trials were designed to explore the administration of the agent and evaluate how the agent was processed.

Studies have evaluated effects on pain scores and changes in inflammation after 8 weeks. Initial research protocols focused on starting the agent at a specific level.

  • Study Design: Double-blind, randomized, placebo-controlled trial.
  • Participant Cohort: 45 adults (ages 35–65) diagnosed with active Disease X.
  • Key Finding: Studies focused on individuals with mild-to-moderate symptoms. The study reported that all participants completed the treatment course.

Trials Focused on Acute Flare-Ups

Subsequent research examined the agent’s effects in individuals experiencing acute flare-ups. A Phase II trial evaluated the potential for an effect shortly after treatment initiation. Research examined the agent’s effect on joint stiffness.

  • Study Design: Open-label, non-randomized trial.
  • Duration: 4 weeks.
  • Study Population: Study procedures included elderly patients to evaluate how the agent was processed.

Long-Term Outcomes and Observational Data

Long-term observational studies have followed patient cohorts for up to 3 years. These studies explored the correlation between treatment and the subsequent rate of surgery for Disease X. Research protocols specified that participants did not consume alcohol during the study period.

  • Key Uncertainty: Evidence remains limited on the agent’s long-term impact on overall quality of life.
  • Future Research: Further research is necessary to compare the agent to standard treatments. It is not yet clear whether the agent can alter the long-term progression of Disease X.

Frequently Asked Questions (FAQ)

Common questions about Alamag (FAQ)


Q: How quickly can I expect Alamag to start working for heartburn relief?

A: Official information indicates that Alamag, like other combination antacids, is designed to provide immediate, temporary relief of heartburn symptoms. The active ingredients are inorganic salts that work by neutralizing existing acid upon contact in the stomach, which allows for a rapid onset of action.

Q: Does Alamag treat the cause of acid reflux or just the symptoms?

A: According to the official product classification, Alamag is an antacid, which means its primary role is to provide immediate, temporary relief of symptoms caused by excess stomach acid. It works by neutralizing the acid and does not treat or cure the underlying cause of acid reflux.

Q: Is Alamag the same as Maalox or Mylanta, or is there a difference?

A: Alamag is the brand name for a combination of Aluminum Hydroxide and Magnesium Hydroxide. Other over-the-counter brands, such as Mylanta or Maalox, may contain the same active ingredients. While the therapeutic action is similar, differences can exist in specific inactive ingredients, flavorings, and product strengths across different brands.

Q: Is it normal to experience a change in bowel movements (constipation or diarrhea) when taking Alamag?

A: Changes in the gastrointestinal system, specifically diarrhea and constipation, are officially documented as uncommon side effects. Alamag is a combination product where the aluminum component can cause constipation and the magnesium component can cause diarrhea; the combination is designed to help balance these opposing effects.

Q: Can Alamag cause me to feel unusually tired or weak?

A: Official information indicates that unusual tiredness and muscle weakness are documented symptoms related to a potential metabolic side effect called hypophosphatemia (low phosphate levels). This risk is typically associated with high-dose or very long-term use of aluminum-containing antacids.

Q: Does Alamag interact with common vitamins or mineral supplements like iron?

A: Yes, regulatory documents indicate that Alamag can interfere with the absorption of other substances, including oral Iron salts and supplements. To minimize this potential interaction, it is generally advised to separate the dose of Alamag and these supplements by at least two hours.

Q: Is Alamag generally considered safe to use during pregnancy?

A: While some regulatory authorities do not list an absolute contra-indication, official labels advise that the use of Alamag during pregnancy should be discussed with a healthcare provider beforehand. Consultation helps ensure an informed decision is made for use during this period.

Q: Are there special considerations for using Alamag while breastfeeding?

A: Official product information advises that the use of the medication while breastfeeding should be discussed with a healthcare provider. The discussion with a healthcare provider can review any specific considerations for use while breastfeeding.

Q: How long does the acid-neutralizing effect of Alamag typically last?

A: The combination of aluminum and magnesium hydroxides provides an intermediate duration of action. The acid-neutralizing effects of this type of antacid are generally reported to last for up to 2 hours per dose.

Q: Why do some people experience a 'chalky' taste when taking the liquid form of Alamag?

A: The metallic or chalky taste is associated with the two active ingredients, which are inorganic metallic salts (aluminum and magnesium hydroxides). Patient advice often suggests taking the liquid suspension with water or milk to help improve the taste and mouthfeel.

Q: Is there a preferred time of day to take Alamag for best results?

A: Official administration guidelines recommend taking Alamag after meals and at bedtime. This timing is generally designed to help manage heartburn and acid reflux symptoms when acid production may be high or when symptoms are most likely to occur.

Q: Can Alamag be taken with or without food?

A: Official instructions specify that Alamag is to be taken after meals and at bedtime. Taking antacids on an empty stomach may cause the acid-neutralizing effect to be shorter-lived.

Q: Can Alamag affect the results of certain medical tests?

A: Official documents highlight that Alamag can bind to and reduce the absorption of many medications. While not explicitly listed for all lab tests, it is possible that the aluminum and magnesium components could potentially impact tests related to those minerals, especially in patients with kidney function issues.

Q: Should I be concerned if I experience mild stomach cramping after taking Alamag?

A: Official safety information notes that abdominal pain can occur as a side effect. While mild cramping is not specifically listed, any severe abdominal pain is a safety finding noted in regulatory documents that is intended to prompt consultation with a healthcare professional.

Q: How does Alamag compare to acid-reducing medications like PPIs (e.g., omeprazole) in terms of action?

A: Alamag is an antacid that works by neutralizing existing acid for rapid relief. Medications like PPIs (Proton Pump Inhibitors) have a different mechanism; they are absorbed into the bloodstream and work to reduce the total amount of acid the stomach produces over a longer period of time.

Q: If I miss a dose of Alamag, what should I do?

A: If you are following a scheduled dosing regimen, patient information generally suggests that if it is almost time for the next scheduled dose, the missed dose is skipped. Doubling the dose to compensate is not recommended by manufacturers.

Q: Does Alamag lose its effectiveness over time with regular use?

A: While official regulatory warnings for loss of effectiveness (tachyphylaxis) are not typically applied to antacids, the official usage instruction is a limit of no more than two consecutive weeks. If symptoms necessitate use beyond the recommended two-week limit, medical consultation is necessary to re-evaluate the condition.

Q: Can Alamag be mixed with water or milk to improve the taste?

A: Yes, some patient education materials suggest that the liquid suspension can be taken mixed with water or milk. This can help to mask the metallic or chalky taste of the active ingredients.

Q: Can Alamag help with gas, bloating, or fullness (if the formulation contains simethicone)?

A: The antacid ingredients themselves only neutralize acid. However, if a specific formulation of the product, such as 'Alamag Plus,' contains the antiflatulent ingredient simethicone, it is intended to also relieve symptoms related to gas, bloating, pressure, or fullness.

Q: Is there a specific age cutoff for who can safely use Alamag?

A: Official labeling states that use in children under 12 years of age requires a physician’s consultation. For general over-the-counter use, this type of antacid is not typically recommended for young children without professional medical advice.

Q: Why is Alamag sometimes used in patients with peptic ulcers?

A: Antacids like Alamag are used because they neutralize the excessive stomach acid that contributes to the pain and irritation of ulcers, such as duodenal ulcers and other gastrointestinal conditions. This helps to promote symptom relief and allow the ulcer lining to heal.

Q: Are there any known inactive ingredients in Alamag that could cause reactions?

A: All official drug labels are required to list every inactive ingredient (excipient) in the product. For individuals with known allergies to common substances like dyes, flavorings, or preservatives, it is important to check the specific product label for a full list of ingredients.

Q: Is there any concern about developing a 'rebound' effect after stopping Alamag?

A: The development of acid rebound, where the stomach produces more acid after stopping the medication, is generally considered not clinically important with this type of combination antacid. However, this effect can sometimes occur with high doses or prolonged use.

Q: Can using Alamag for a week or two indicate a need for different medical treatment?

A: The maximum duration of continuous over-the-counter use is restricted to no more than two consecutive weeks. If your symptoms persist, worsen, or are not fully relieved after two weeks, a medical evaluation by a healthcare provider is generally recommended.

How should Alamag be stored and disposed of?

How to Store and Dispose of Alamag?

The storage and disposal of this combination antacid product must strictly comply with the conditions defined in official regulatory labeling to ensure stability and safety.

Storage Requirements

Alamag must be stored at room temperature and maintained in the container it came in, tightly closed. The product must be protected away from excess heat and moisture; therefore, it should not be stored in a bathroom. For the Oral Suspension, the container should be shaken well before each use to ensure uniform medication stability.

Child-Safety and Disposal

It is a mandatory requirement to store the medicine out of the sight and reach of children, placed in a secure location that is up and away from them, with safety caps locked where applicable. Unused or expired medication must not be discarded via the toilet, drain, or standard household trash. Individuals should consult a pharmacist for the proper instructions on disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alamag found in:

A-Z Index: